Current therapy regimens are based on the molecular classification of breast carcinomas and essentially depend on the hormone receptor (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)) status and proliferative indices (Ki67) of the breast carcinoma [3]. This evidence concerns the gene ESR1 and breast carcinoma.